Fig. 1 · Structure

Documents & Downloads

Icariin

Cat. No. A10464 CAS 489-32-7

PDE5 inhibitor

Icariin is inhibitory to all three PDE5 isoforms that inhibits PDE5A1, A2, and A3 with an IC50 value of 1.0, 0.75, and 1.1 microM, respectively.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Icariin inhibits recombinant human PDE5-mediated cGMP hydrolysis, with an IC50 of 6 ± 1 µM in one purified-enzyme assay. More potent modified analogs in that study are distinct compounds. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PDE5 0.432 μM

Cellular Effect

Cell Line Activity Value Description Reference
NCI/ADR-RES IC50 > 100 μM Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay [PMID: 19523827]
TM3 CC50 > 200 μM Cytotoxicity against mouse TM3 cells assessed as reduction in cell viability measured after 24 hrs by sulforhodamine B assay [PMID: 31091478]

Icariin Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Icariin from 2 published references. In vitro models include purified recombinant human PDE5 catalytic domain, amino acids 537–875.

Icariin In Vitro Studies

In UMR 106 cells, icariin at 10⁻⁸ M for 24 h did not induce ERα- or ERβ-mediated ERE reporter activity, whereas estradiol activated both reporters. This result limits interpretation of icariin as a classical ERE agonist. [2]

Inhibition of recombinant human PDE5

Biochemical assay · Purified recombinant human PDE5 catalytic domain, amino acids 537–875 [1]

Icariin inhibited cGMP hydrolysis. Sildenafil served as a comparator and activity was normalized to no-drug controls. This endpoint does not establish selectivity or the inhibition mode of native icariin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of PDE5-mediated GMP productionIC50 6 ± 1 µM (mean ± SEM; at least three replicates)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Methods give an assay-wide inhibitor range of 0.001–150 µM; a separate native-icariin dilution series is not listed.
Exposure duration
5 min preincubation followed by 15 min reaction at 25°C
Method
HPLC-UV-MS quantification of GMP; 1 nM PDE5 and 0.3 µM cGMP
Vehicle
DMSO, maximum 0.1% of final reaction volume
Reported limits
Native-icariin-specific concentration series and lot identity are not specified; the >95% purity statement concerns synthesized analogs.
Methods and source locations

Compound reported in the paper: Icariin; Compound label in the paper: icariin

Compound-level preclinical findings; no validation of an Adooq lot or clinical efficacy.

Fig. 3 and caption; Results: Select icariin analogs exhibit enhanced inhibition potencies; Methods: General procedures; Enzyme inhibition and kinetics measurement

Inhibition of PDE5-mediated GMP production: Four-parameter nonlinear regression of activity normalized to no-drug controls. Sildenafil IC50: 0.028 ± 0.007 µM. — Fig. 3 image/caption; Results: Select icariin analogs exhibit enhanced inhibition potencies; Methods: Enzyme inhibition and kinetics measurement

Negative ERE reporter response in UMR 106 cells

Cell-based study · Rat osteoblast-like UMR 106 cells transfected with ERα or ERβ, ERE-firefly and pRL-TK Renilla reporters [2]

Icariin did not induce ERE-dependent reporter activity under the tested condition, while estradiol activated both receptor reporter systems. This limits a simple classical ERE-agonist interpretation; it does not exclude other ER-associated effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERα- and ERβ-mediated ERE luciferase activityQualitative reporter response No induction by icariin; estradiol induced both reporters (P < 0.001 versus control). Mean ± SEM from three independent experiments.[2]

Literature-Reported Treatment Conditions

Treatment concentration
10⁻⁸ M icariin; 10⁻⁸ M 17β-oestradiol comparator
Exposure duration
24 h treatment, beginning 5 h after transfection
Method
Dual luciferase reporter assay; firefly normalized to Renilla
Vehicle
Vehicle control; composition not specified in the reporter methods
Reported limits
Exact numerical reporter values are not tabulated; none are estimated from bars.
Methods and source locations

Compound reported in the paper: Icariin; Compound label in the paper: icariin

Compound-level preclinical findings; no validation of an Adooq lot or clinical efficacy.

Fig. 6A–B and caption; Results: Effects of icariin on ERα or ERβ-mediated, ERE-dependent, luciferase activities; Methods: Transient transfection and ER-mediated luciferase activity assay; Materials

ERα- and ERβ-mediated ERE luciferase activity: Normalized dual luciferase assay with vehicle and estradiol controls. — Fig. 6A–B image/caption; corresponding Results; Methods: Transient transfection and ER-mediated luciferase activity assay

Icariin In Vivo Studies

In ovariectomized C57BL/6J mice, daily oral icariin for six weeks increased distal-femur bone mineral density and polar stress-strain index versus vehicle. Uterine index did not increase. These are model-specific preclinical outcomes. [2]

Bone outcomes in ovariectomized mice

Animal study · Female C57BL/6J mice: sham, OVX vehicle, OVX estradiol and OVX icariin [2]

Six weeks of oral icariin increased distal-femur BMD and polar SSI versus OVX vehicle. It did not reproduce estradiol effects on uterine index or weight gain. Results apply to this growing-mouse estrogen-deficiency model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Distal-femur total bone mineral densityBMD Icariin 454 ± 7; OVX 393 ± 8; sham 462 ± 11; estradiol 486 ± 17 mg·ccm⁻¹. Mean ± SEM, n=7–8/group. Icariin versus OVX: P < 0.01.[2]
Distal-femur trabecular bone mineral densityBMD Icariin 443 ± 6.39; OVX 386 ± 10; sham 461 ± 14; estradiol 494 ± 23 mg·ccm⁻¹. Mean ± SEM, n=7–8/group. Icariin versus OVX: P < 0.05.[2]
Distal-femur polar stress-strain indexPolar SSI Icariin 0.64 ± 0.04; OVX 0.32 ± 0.05; sham 0.83 ± 0.11; estradiol 0.71 ± 0.06 mm³. Mean ± SEM, n=7–8/group. Icariin versus OVX: P < 0.01.[2]
Uterus/body weight ratioUterine index Icariin 0.43 ± 0.04; OVX 0.36 ± 0.06; sham 1.69 ± 0.11; estradiol 2.69 ± 0.18 mg·g⁻¹. Mean ± SEM, n=7–8/group. Icariin did not increase uterine index versus OVX.[2]

Conditions shared by the study groups

Route
Oral
Frequency
Daily
Treatment course
6 weeks, starting after 18 days of surgical recovery
Vehicle
Vehicle composition not specified in Animal studies
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
OVX + icariin
0.3 mg·g⁻¹·day⁻¹
OVX + vehicle; sham + vehicle; separate OVX + 17β-oestradiol group (4 µg·g⁻¹·day⁻¹ orally)Higher distal-femur total/trabecular BMD and polar SSI versus OVX vehicle. Uterine index was not increased. Eight mice allocated per group; tables report 7–8 per group.[2]
OVX + icariin
Model: Female C57BL/6J mice ovariectomized at 1 month of age
Reported limits: Reason for endpoint n=7–8 rather than allocated n=8 is not explained in the animal methods/table notes.
Methods and source locations

Compound reported in the paper: Icariin; Compound label in the paper: icariin

Compound-level preclinical findings; no validation of an Adooq lot or clinical efficacy.

Methods: Animal studies; BMD analysis by pQCT; Materials; Results and Tables 2–3

Distal-femur total bone mineral density: Peripheral quantitative computed tomography. — Table 3 (total BMD column and footnotes); Methods: BMD analysis by pQCT

Distal-femur trabecular bone mineral density: Peripheral quantitative computed tomography. — Table 3 (trabecular BMD column and footnotes); Methods: BMD analysis by pQCT

Distal-femur polar stress-strain index: Computed pQCT strength-related index. — Table 3 (polar SSI column and footnotes); Methods: BMD analysis by pQCT

Uterus/body weight ratio: Uterine weight normalized to final body weight. — Table 2 and footnotes; Results: Effects of icariin on body weight, uterine index and biochemical parameters

OVX + icariin · Methods: Animal studies; BMD analysis by pQCT; Tables 2–3 and notes

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 489-32-7
Applications PDE5 inhibitor
Formula C33H40O15
Molecular Weight 676.7
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 46 mg/mL (67.98 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Icariin Research References

  1. [1] Yasmin Chau, Fu-Shuang Li, Olesya Levsh, et al. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5 PLOS ONE (2019). PMID: 31539416 DOI: 10.1371/journal.pone.0222803 Source material
  2. [2] Sao-Keng Mok, Wen-Fang Chen, Wan-Ping Lai, et al. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells British Journal of Pharmacology (2010). PMID: 20128811 DOI: 10.1111/j.1476-5381.2009.00593.x Source material

Added to your cart

View Cart Checkout
Loading...